ArticleFrontiers in immunology2024

Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.

Xiangjun Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.